Research Topics
Genomes and Genes
Species | Michael E ThaseSummaryAffiliation: University of Pittsburgh Country: USA Publications
| Collaborators
|
Detail Information
Publications
Depression and sleep: pathophysiology and treatmentMichael E Thase
University of Pittsburgh Medical Center, PA, USA
Dialogues Clin Neurosci 8:217-26. 2006..Cognitive behavioral therapy and other nonpharmacologic strategies are also helpful...
Remission rates following antidepressant therapy with bupropion or selective serotonin reuptake inhibitors: a meta-analysis of original data from 7 randomized controlled trialsMichael E Thase
Department of Psychiatry, University of Pittsburgh Medical Center, Pittsburgh, PA 15213 2593, USA
J Clin Psychiatry 66:974-81. 2005....- Correlates and consequences of chronic insomniaMichael E Thase
Department of Psychiatry, Western Psychiatric Institute and Clinic, University of Pittsburgh Medical Center, Pittsburgh, PA 15213 2593, USA
Gen Hosp Psychiatry 27:100-12. 2005..New and emerging anti-insomnia agents may prove useful in the long-term treatment of chronic insomnia. Further research is needed to establish the benefits of such treatment... - Cognitive therapy versus medication in augmentation and switch strategies as second-step treatments: a STAR*D reportMichael E Thase
Department of Psychiatry, University of Pittsburgh Medical Center, 3811 OHara St, Pittsburgh, PA 15213 2593, and Massachusetts General Hospital, USA
Am J Psychiatry 164:739-52. 2007..Cognitive therapy was compared with medication augmentation and switch strategies... - Introduction: new directions in the treatment of atypical depressionMichael E Thase
Department of Psychiatry, University of Pittsburgh Medical Center School of Medicine, and the Western Psychiatric Institute and Clinic, Pittsburgh, PA 15213, USA
J Clin Psychiatry 68:4-9. 2007 - A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorderMichael E Thase
Western Psychiatric Institute and Clinic, University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
J Clin Psychiatry 68:224-36. 2007..Two parallel, 8-week double-blind studies compared olanzapine/fluoxetine combination, olanzapine, and fluoxetine in outpatients with treatment-resistant depression (TRD)... - The failure of evidence-based medicine to guide treatment of antidepressant nonrespondersMichael E Thase
University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA
J Clin Psychiatry 67:1833-5. 2006 - Relative antidepressant efficacy of venlafaxine and SSRIs: sex-age interactionsMichael E Thase
Department of Psychiatry, University of Pittsburgh Medical Center, Western Psychiatric Institute and Clinic, 3811 O Hara Street, Pittsburgh, PA 15213 2593, USA
J Womens Health (Larchmt) 14:609-16. 2005..To investigate whether differences in antidepressant efficacy are moderated by an interaction of age and gender... - Bipolar depression: issues in diagnosis and treatmentMichael E Thase
Department of Psychiatry, University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA
Harv Rev Psychiatry 13:257-71. 2005..The optimal duration of maintenance antidepressant therapy has not been established empirically and, until better evidence-based guidelines are established, should be determined on a case-by-case basis... - Preventing relapse and recurrence of depression: a brief review of therapeutic optionsMichael E Thase
Department of Psychiatry, University of Pittsburgh Medical Center, Pennsylvania 15213 2593, USA
CNS Spectr 11:12-21. 2006.... - Efficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebo-controlled study (the BOLDER II study)Michael E Thase
Western Psychiatric Institute and Clinic, University of Pittsburgh Medical Center, Pittsburgh, PA 15213 2593, USA
J Clin Psychopharmacol 26:600-9. 2006..This study demonstrates that quetiapine monotherapy is an effective and well-tolerated treatment for depressive episodes in bipolar disorder, confirming the results observed from a previous study (BipOLar DEpRession [BOLDER] I)... - Pharmacotherapy of bipolar depression: an updateMichael E Thase
University of Pittsburgh Medical Center, Western Psychiatric Institute and Clinic, 3811 O Hara St, Pittsburgh, PA 15213 2593, USA
Curr Psychiatry Rep 8:478-88. 2006..Antidepressants--particularly selective serotonin reuptake inhibitors and bupropion--are indicated when mood stabilizers are ineffective and for "breakthrough" depressions... - Managing depressive and anxiety disorders with escitalopramMichael E Thase
University of Pittsburgh Medical Centre, Western Psychiatric Institute and Clinic, Pittsburgh, PA 15213 2593, USA
Expert Opin Pharmacother 7:429-40. 2006..Pharmacoeconomic models suggest that the greater drug acquisition cost of this patent-protected compound may be offset by greater efficacy (relative to generic citalopram) and tolerability (compared with extended release venlafaxine)... - Modafinil augmentation of SSRI therapy in patients with major depressive disorder and excessive sleepiness and fatigue: a 12-week, open-label, extension studyMichael E Thase
Division of Adult Academic Psychiatry, University of Pittsburgh Medical Center, Pittsburgh, PA, USA
CNS Spectr 11:93-102. 2006..Placebo-controlled studies indicate that modafinil, a wake-promoting agent, may relieve residual symptoms... - Treatment of anxiety disorders with venlafaxine XRMichael E Thase
University of Pittsburgh Medical Center, Pittsburgh, PA 15213, USA
Expert Rev Neurother 6:269-82. 2006..Concerns about safety in overdose have also recently emerged. Despite these caveats, venlafaxine XR is an effective and generally well-tolerated option for treatment of anxiety disorders... - Bipolar depression: diagnostic and treatment considerationsMichael E Thase
Western Psychiatric Institute and Clinic, University of Pittsburgh Medical Center, PA 15123 2593, USA
Dev Psychopathol 18:1213-30. 2006..Studies of adults indicate that several forms of focused psychotherapy may improve longer term outcomes... - Introduction: the dual-action debate: does pharmacology matter?Michael E Thase
Department of Psychiatry, University of Pittsburgh Medical Center, 3811 O Hara St, Pittsburgh, PA 15213 2593, USA
J Clin Psychiatry 65:3-4. 2004 - Therapeutic alternatives for difficult-to-treat depression: a narrative review of the state of the evidenceMichael E Thase
Department of Psychiatry, University of Pittsburgh Medical Center, Pittsburgh, PA 15213 2593, USA
CNS Spectr 9:808-16, 818-21. 2004.... - Treatment with venlafaxine extended release after SSRI nonresponse or intolerance: a randomized comparison of standard- and higher-dosing strategiesMichael E Thase
University of Pittsburgh Medical Center, Department of Psychiatry, Pittsburgh, PA 15213 2593, USA
J Clin Psychopharmacol 26:250-8. 2006.... - Treatment of recurrent depression: an alternate viewpointMichael E Thase
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA
CNS Drugs 17:1119-22. 2003 
Income and attrition in the treatment of depression: a STAR*D reportDiane Warden
Department of Psychiatry, The University of Texas Southwestern Medical Center at Dallas, Dallas, Texas 75390 9086, USA
Depress Anxiety 26:622-33. 2009..This report assessed whether attrition rates and predictors of attrition differed among depressed outpatients with different income levels...- What predicts attrition in second step medication treatments for depression?: a STAR*D ReportDiane Warden
Department of Psychiatry, The University of Texas Southwestern Medical Center at Dallas, Dallas, TX 75390 9119, USA
Int J Neuropsychopharmacol 12:459-73. 2009..Focus on patients with attrition risk factors for medication augmentation or switch strategies may enhance retention and improve outcomes... - Acceptability of second-step treatments to depressed outpatients: a STAR*D reportStephen R Wisniewski
Department of Psychiatry, Epidemiology Data Center, Graduate School of Public Health, University of Pittsburgh, Pittsburgh, PA 15261, and Clinical Psychopharmacology Unit, Massachusetts General Hospital, Boston, USA
Am J Psychiatry 164:753-60. 2007..This study sought to identify factors that affect patients' willingness to accept different second-step treatment approaches... - Depressive illness burden associated with complex polypharmacy in patients with bipolar disorder: findings from the STEP-BDJoseph F Goldberg
Department of Psychiatry, Mount Sinai School of Medicine, New York, NY, USA
J Clin Psychiatry 70:155-62. 2009..Many patients with bipolar disorder receive multi-drug treatment regimens, but the distinguishing profiles of patients who receive complex pharmacologies have not been established... - Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D reportA John Rush
Department of Psychiatry, University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd, Dallas, TX 75390 9086, USA
Am J Psychiatry 163:1905-17. 2006..This report describes the participants and compares the acute and longer-term treatment outcomes associated with each of four successive steps in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial... - Randomized, placebo-controlled trial of nefazodone maintenance treatment in preventing recurrence in chronic depressionAlan J Gelenberg
Department of Psychiatry, Health Sciences Center, University of Arizona, PO Box 245002, Tucson, AZ 85724-5002, USA
Biol Psychiatry 54:806-17. 2003..8%). Somnolence was significantly greater among the patients taking active medication (15.4%), compared with placebo (4.6%). CONCLUSIONS: Nefazodone is well-tolerated and is an effective maintenance therapy for chronic forms of MDD... - Medication augmentation after the failure of SSRIs for depressionMadhukar H Trivedi
Mood Disorder Program and Clinic, Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX 75390 9119, USA
N Engl J Med 354:1243-52. 2006..Although clinicians frequently add a second medication to an initial, ineffective antidepressant drug, no randomized controlled trial has compared the efficacy of this approach... - Sequenced treatment alternatives to relieve depression (STAR*D): rationale and designA John Rush
Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, Texas 75390 9086, USA
Control Clin Trials 25:119-42. 2004..Participants with an adequate symptomatic response may enter the 12-month naturalistic follow-up phase with brief monthly and more complete quarterly assessments... - Which symptoms predict recurrence of depression in women treated with maintenance interpersonal psychotherapy?Alexandre Y Dombrovski
Western Psychiatric Institute and Clinic, Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA
Depress Anxiety 25:1060-6. 2008..We therefore examined the impact of persistent symptoms, including mood, insomnia, and anxiety symptoms, on time to recurrence in women receiving maintenance interpersonal psychotherapy (IPT-M) for recurrent depression... - An integrated analysis of olanzapine/fluoxetine combination in clinical trials of treatment-resistant depressionMadhukar H Trivedi
Department of Psychiatry, University of Texas Southwestern Medical Center at Dallas, Dallas, TX 75390 9119, USA
J Clin Psychiatry 70:387-96. 2009..To evaluate the efficacy of olanzapine/fluoxetine combination (OFC) versus olanzapine or fluoxetine monotherapy across all clinical trials of treatment-resistant depression sponsored by Eli Lilly and Company... - Clinical features associated with poor pharmacologic adherence in bipolar disorder: results from the STEP-BD studyRoy H Perlis
Bipolar Clinic and Research Program, Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
J Clin Psychiatry 71:296-303. 2010..Poor medication adherence is common among bipolar patients... - Can phase III trial results of antidepressant medications be generalized to clinical practice? A STAR*D reportStephen R Wisniewski
Epidemiology Data Center, Graduate School of Public Health, University of Pittsburgh, 127 Parran Hall, 130 DeSoto St, Pittsburgh, PA 15261, USA
Am J Psychiatry 166:599-607. 2009.... - Prevention of recurrent episodes of depression with venlafaxine ER in a 1-year maintenance phase from the PREVENT StudyJames H Kocsis
Department of Psychiatry, Weill Cornell Medical College, New York, NY 10012, USA
J Clin Psychiatry 68:1014-23. 2007..To test the long-term efficacy and safety of venlafaxine extended-release (ER) in preventing recurrence in patients with major depression... - Bupropion-SR, sertraline, or venlafaxine-XR after failure of SSRIs for depressionA John Rush
Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX 75390 9086, USA
N Engl J Med 354:1231-42. 2006..After unsuccessful treatment for depression with a selective serotonin-reuptake inhibitor (SSRI), it is not known whether switching to one antidepressant is more effective than switching to another... - Primary versus specialty care outcomes for depressed outpatients managed with measurement-based care: results from STAR*DBradley N Gaynes
Department of Psychiatry, University of North Carolina School of Medicine, Chapel Hill, NC, USA
J Gen Intern Med 23:551-60. 2008..Whether the acute outcomes of major depressive disorder (MDD) treated in primary (PC) or specialty care (SC) settings are different is unknown... - Sexual function and satisfaction in the treatment of chronic major depression with nefazodone, psychotherapy, and their combinationJohn Zajecka
Department of Psychiatry, Rush-Presbyterian-St. Luke's Medical Center, 1725 W. Harrison Street, Suite 955, Chicago, IL 60612, USA
J Clin Psychiatry 63:709-16. 2002..Treatment with nefazodone, CBASP, and combined treatment improved sexual interest/satisfaction, with greatest improvement observed with combined treatment... - Randomized, placebo-controlled trial of fluoxetine for acute treatment of minor depressive disorderLewis L Judd
Department of Psychiatry, University of California, San Diego, 9500 Gilman Dr, La Jolla, CA 92093 0603, USA
Am J Psychiatry 161:1864-71. 2004..Minor depressive disorder is both common and associated with significant psychosocial impairment. This study examined antidepressant treatment efficacy in a large group of patients with minor depressive disorder... - The prospective course of rapid-cycling bipolar disorder: findings from the STEP-BDChristopher D Schneck
Department of Psychiatry, University of Colorado Health Sciences Center, Denver, CO 80220, USA
Am J Psychiatry 165:370-7; quiz 410. 2008..In a naturalistic follow-up of adult bipolar patients, the authors examined the contributions of demographic, phenomenological, and clinical variables, including antidepressant use, to prospectively observed mood episode frequency... - Bipolar disorder center for Pennsylvanians: implementing an effectiveness trial to improve treatment for at-risk patientsDavid J Kupfer
Department of Psychiatry, University of Pittsburgh School of Medicine, Western Psychiatric Institute and Clinic, 3811 O Hara St, Pittsburgh, PA 15213, USA
Psychiatr Serv 60:888-97. 2009..This report highlights the methods used to recruit, screen, and enroll a cohort of difficult-to-recruit individuals with bipolar disorder... - Cognitive behavioral analysis system of psychotherapy and brief supportive psychotherapy for augmentation of antidepressant nonresponse in chronic depression: the REVAMP TrialJames H Kocsis
Department of Psychiatry, Weill Cornell Medical College, 1300 York Ave, New York, NY 10065, USA
Arch Gen Psychiatry 66:1178-88. 2009..Previous studies have found that few chronically depressed patients remit with antidepressant medications alone... - Differential effects of nefazodone and cognitive behavioral analysis system of psychotherapy on insomnia associated with chronic forms of major depressionMichael E Thase
Department of Psychiatry, University of Pittsburgh School of Medicine, Western Psychiatric Institute and Clinic, PA 15213 2593, USA
J Clin Psychiatry 63:493-500. 2002..As nefazodone-mediated blockade of serotonin-2 receptors may directly relieve insomnia associated with depression, we examined the more specific effects of CBASP and nefazodone, singly and in combination, on sleep disturbances... - Clinical correlates of the worsening or emergence of suicidal ideation during SSRI treatment of depression: an examination of citalopram in the STAR*D studySidney Zisook
Department of Psychiatry, University of California, San Diego, San Diego VA Medical Center, San Diego, California, USA
J Affect Disord 117:63-73. 2009..The purpose of this study was to determine whether, and in whom, treatment of MDD is associated with increased or emergent SI... - Chronic forms of major depression are still undertreated in the 21st century: systematic assessment of 801 patients presenting for treatmentJames H Kocsis
Department of Psychiatry, Weill Cornell Medical Center, 525 East 68th Street, New York, NY 10021, USA
J Affect Disord 110:55-61. 2008..These results and the consistency of similar results over time point to the dire need for patient and provider education regarding the signs and symptoms of depression and its treatment... - Insomnia and objectively measured sleep disturbances predict treatment outcome in depressed patients treated with psychotherapy or psychotherapy-pharmacotherapy combinationsWendy M Troxel
Department of Psychiatry and Psychology, University of Pittsburgh, Pittsburgh, PA 15213, USA
J Clin Psychiatry 73:478-85. 2012..The present study is a secondary analysis that examines the degree to which insomnia, objective sleep disturbances, or their combination predicts depression remission following pharmacotherapy and/or psychotherapy treatment... - Does recovery from substance use disorder matter in patients with bipolar disorder?Roger D Weiss
Department of Psychiatry, Harvard Medical School, Boston, USA
J Clin Psychiatry 66:730-5; quiz 808-9. 2005..To examine the potential impact of recovery from substance use disorder (SUD) on the course of bipolar disorder among patients diagnosed with both bipolar and substance use disorders according to DSM-IV criteria... - Differential effects of treatments for chronic depression: a latent growth model reanalysisNiklaus Stulz
Department of Psychiatry, University of Pennsylvania Philadelphia, PA 19104, USA
J Consult Clin Psychol 78:409-19. 2010.... - Sustained gamma-band EEG following negative words in depression and schizophreniaGreg J Siegle
University of Pittsburgh School of Medicine, Pittsburgh, PA, USA
Int J Psychophysiol 75:107-18. 2010..This study examined whether there were group differences in baseline and sustained gamma-band EEG following emotional stimuli in healthy adults as well as adults with depression and schizophrenia... - Lithium treatment -- moderate dose use study (LiTMUS) for bipolar disorder: rationale and designAndrew A Nierenberg
Department of Psychiatry, Massachusetts General Hospital, Boston, MA 02114, USA
Clin Trials 6:637-48. 2009..Recent data indicate that lithium use for bipolar disorder has declined over the last decade and that lithium largely has been replaced with alternate, commercially promoted medications that may or may not result in better outcomes... - REVAMP - Research Evaluating the Value of Augmenting Medication with Psychotherapy: rationale and designMadhukar H Trivedi
Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX, USA
Psychopharmacol Bull 41:5-33. 2008.... - Two-year outcomes for interpersonal and social rhythm therapy in individuals with bipolar I disorderEllen Frank
Western Psychiatric Institute and Clinic, Department of Psychiatry, University of Pittsburgh School of Medicine, Pittsburgh, PA 15213, USA
Arch Gen Psychiatry 62:996-1004. 2005..Recent investigations have demonstrated benefits from the addition of psychoeducation or psychotherapy to pharmacotherapy in this population... - Self-reported depressive symptom measures: sensitivity to detecting change in a randomized, controlled trial of chronically depressed, nonpsychotic outpatientsA John Rush
Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX 75390 9086, USA
Neuropsychopharmacology 30:405-16. 2005..Global patient ratings such as the PGI-I, as opposed to specific item-based ratings, provide less valid findings... - Patient preference as a moderator of outcome for chronic forms of major depressive disorder treated with nefazodone, cognitive behavioral analysis system of psychotherapy, or their combinationJames H Kocsis
Department of Psychiatry, Weill Cornell Medical College, New York, N Y, USA
J Clin Psychiatry 70:354-61. 2009..We hypothesized that patient preference at baseline would interact with treatment group to differentially affect treatment outcome... - Association study of 21 circadian genes with bipolar I disorder, schizoaffective disorder, and schizophreniaHader A Mansour
Department of Psychiatry, University of Pittsburgh School of Medicine, Western Psychiatric Institute and Clinic, Pittsburgh, PA 15213, USA
Bipolar Disord 11:701-10. 2009..The results are plausible, based on prior studies of circadian abnormalities. As replications have not been attempted uniformly, we evaluated representative, common polymorphisms in all three disorders... - Clinical significance of lifetime panic spectrum symptoms in the treatment of patients with bipolar I disorderEllen Frank
Department of Psychiatry, Western Psychiatric Institute and Clinic, Pittsburgh, PA 15213, USA
Arch Gen Psychiatry 59:905-11. 2002..We hypothesized that lifetime panic spectrum features would be associated with higher levels of suicidal ideation and a poorer response to acute treatment of the index mood episode in this patient population... - Effect of age at onset on the course of major depressive disorderSidney Zisook
Department of Psychiatry, University of California, San Diego, CA 92093, USA
Am J Psychiatry 164:1539-46. 2007..This report assesses whether age at onset defines a specific subgroup of major depressive disorder in 4,041 participants who entered the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study... - Background and rationale for the sequenced treatment alternatives to relieve depression (STAR*D) studyMaurizio Fava
Department of Psychiatry, Massachusetts General Hospital, Boston, MA, USA
Psychiatr Clin North Am 26:457-94, x. 2003..This article provides the overall rationale for STAR*D and details the rationale for key design, measurement, and analytic features of the study... - The 16-Item Quick Inventory of Depressive Symptomatology (QIDS), clinician rating (QIDS-C), and self-report (QIDS-SR): a psychometric evaluation in patients with chronic major depressionA John Rush
Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, Texas 75390-9086, USA
Biol Psychiatry 54:573-83. 2003..The QIDS-SR(16) has highly acceptable psychometric properties, which supports the usefulness of this brief rating of depressive symptom severity in both clinical and research settings... - A comparison of baseline sociodemographic and clinical characteristics between major depressive disorder patients with and without diabetes: a STAR*D reportCharlene J Bryan
School of Nursing, University of Pennsylvania, Philadelphia, Pennsylvania, USA
J Affect Disord 108:113-20. 2008.... - Update on partial response in depressionMichael E Thase
Department of Psychiatry, University of Pennsylvania School of Medicine, Philadelphia Veterans Affairs Medical Center, and Pittsburgh Medical Center, Philadelphia and Pittsburgh, USA
J Clin Psychiatry 70:4-9. 2009..Although studies on predictive factors have not yielded definitive results, clinicians in practice often select adjunctive agents that target patients' persistent symptoms... - Validity of the distinction between primary and secondary substance use disorder in patients with bipolar disorder: data from the first 1000 STEP-BD participantsMark D Fossey
Department of Psychiatry, University of Oklahoma College of Medicine Tulsa, Tulsa, Oklahoma 74135, USA
Am J Addict 15:138-43. 2006..The primary/secondary distinction for SUD is not valid when variations in the age of onset of the non-SUD are linked to course characteristics... - Report by the ACNP Task Force on response and remission in major depressive disorderA John Rush
Department of Psychiatry, University of Texas Southwestern Medical Center, Dallas, TX 75390 9086, USA
Neuropsychopharmacology 31:1841-53. 2006..Research to evaluate these recommendations empirically is needed... - Selecting appropriate treatments for maintenance therapy for bipolar disorderMichael E Thase
Department of Psychiatry, University of Pennsylvania School of Medicine and Philadelphia Veterans Affairs Medical Center, Philadelphia, PA 19104, USA
J Clin Psychiatry 69:28-35. 2008..Additionally, several forms of psychotherapy specifically tailored to the needs of people with bipolar disorder should be considered as an adjunct to medication... - Brief report: paroxetine in younger and adult individuals at high risk for suicideMark S Bauer
Department of Psychiatry, Brown University, USA
Psychopharmacol Bull 39:31-7. 2006..In fact, the younger group showed a trend for decreased suicidality (P = .13). Thus, increased suicidality risk with paroxetine exposure does not extend to this other high-risk mood disordered population, even among younger individuals... - The state of knowledge of chronic depressionAlan J Gelenberg
Department of Psychiatry, Arizona Health Sciences Center, Tucson, AZ, USA
J Clin Psychiatry 67:179-84. 2006 - Symptomatic and syndromal anxiety in chronic forms of major depression: effect of nefazodone, cognitive behavioral analysis system of psychotherapy, and their combinationPhilip T Ninan
Department of Psychiatry, Emory University School of Medicine, Atlanta, GA 30329, USA
J Clin Psychiatry 63:434-41. 2002..Among patients with a concurrent anxiety disorder, nefazodone. either alone or in combination with CBASP, improves anxiety symptoms faster than CBASP alone, independent of depressive symptom reduction... - Management of patients with treatment-resistant depressionMichael E Thase
Department of Psychiatry, University of Pittsburgh Medical Center, Western Psychiatric Institute and Clinic, Pittsburgh, PA, USA
J Clin Psychiatry 69:e8. 2008.... - Modafinil augmentation of selective serotonin reuptake inhibitor therapy in MDD partial responders with persistent fatigue and sleepinessMaurizio Fava
Depression Clinical and Research Program, Massachusetts General Hospital, Boston, MA 02114, and Department of Psychiatry, University of Pittsburgh Medical Center, PA, USA
Ann Clin Psychiatry 19:153-9. 2007..This study evaluated modafinil in patients with major depressive disorder (MDD) who were partial responders to adequate selective serotonin reuptake inhibitor (SSRI) therapy and excessive sleepiness and fatigue... - Augmentation strategies for depression: history and conceptsMichael E Thase
University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
CNS Spectr 12:3-5. 2007 - Focus on bipolar disorder treatmentCharles L Bowden
Department of Psychiatry, University of Texas Health Science Center at San Antonio, TX, USA
J Clin Psychiatry 66:1598-609. 2005 - A double-blind comparison between bupropion XL and venlafaxine XR: sexual functioning, antidepressant efficacy, and tolerabilityMichael E Thase
Department of Psychiatry, University of Pittsburgh Medical Center, Western Psychiatric Institute, Pittsburgh, PA, USA
J Clin Psychopharmacol 26:482-8. 2006..In conclusion, in this patient population (ie, relatively young, sexually active outpatients), bupropion XL was at least as effective as venlafaxine XR and had a significantly more favorable sexual side effect profile... - Efficacy of duloxetine and selective serotonin reuptake inhibitors: comparisons as assessed by remission rates in patients with major depressive disorderMichael E Thase
Department of Psychiatry, University of Pennsylvania School of Medicine, 3535 Market Street, Philadelphia, PA 19104, USA
J Clin Psychopharmacol 27:672-6. 2007.... - Electroencephalographic sleep profiles in single-episode and recurrent unipolar forms of major depression: II. Comparison during remissionRipu D Jindal
Department of Psychiatry, University of Pittsburgh School of Medicine, Western Psychiatric Institute and Clinic, Pittsburgh, Pennsylvania 15213, USA
Biol Psychiatry 51:230-6. 2002..Resolution of this issue requires longitudinal and family studies... - A randomized, double-blind, placebo-controlled study of the effect of sustained-release bupropion on blood pressure in individuals with mild untreated hypertensionMichael E Thase
Department of Psychiatry, University of Pennsylvania School of Medicine, 3535 Market Street, Philadelphia, PA 19104, USA
J Clin Psychopharmacol 28:302-7. 2008..28 vs -0.64 beats/min; Delta = 2.92, P = 0.004). Although only minor effects on blood pressure were observed in this trial, an infrequent association of bupropion therapy and treatment-emergent hypertension cannot be ruled out... - Persistent posttraumatic stress disorder following September 11 in patients with bipolar disorderMark H Pollack
Department of Psychiatry, Massachusetts General Hospital, Boston, Mass, USA
J Clin Psychiatry 67:394-9. 2006.... - Retrospective age at onset of bipolar disorder and outcome during two-year follow-up: results from the STEP-BD studyRoy H Perlis
Bipolar Clinical and Research Program, Department of Psychiatry, Massachusetts General Hospital and Harvard Medical School, ACC 812 15 Parkman Street, Boston, MA 02114, USA
Bipolar Disord 11:391-400. 2009..Symptoms of bipolar disorder are increasingly recognized among children and adolescents, but little is known about the course of bipolar disorder among adults who experience childhood onset of symptoms... - Therapeutic alliance in depression treatment: controlling for prior change and patient characteristicsDaniel N Klein
Department of Psychology and Psychiatry, State University of New York at Stony Brook, 11794 2500, USA
J Consult Clin Psychol 71:997-1006. 2003..Patients receiving combination treatment reported stronger alliances with their psychotherapists than patients receiving CBASP alone. However, the impact of the alliance on outcome was similar for both treatment conditions... - A comparison of mirtazapine and nortriptyline following two consecutive failed medication treatments for depressed outpatients: a STAR*D reportMaurizio Fava
Depression Clinical and Research Program, Massachusetts General Hospital, Bulfinch 351, 55 Fruit St, Boston, MA 02114, USA
Am J Psychiatry 163:1161-72. 2006.... - Placebo-controlled continuation treatment with mirtazapine: acute pattern of response predicts relapseAndrew A Nierenberg
Havard Medical School, Massachusetts General Hospital, Boston, MA 02114, USA
Neuropsychopharmacology 29:1012-8. 2004..The low relapse rate for patients with an acute placebo pattern switched to placebo suggests specific drug effect played a smaller role in their initial improvement... - Dropouts versus completers among chronically depressed outpatientsBruce A Arnow
Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA 94305 5722, United States
J Affect Disord 97:197-202. 2007..Premature termination is common among patients treated for depression with either pharmacotherapy or psychotherapy. Yet little is known about factors associated with premature treatment termination among depressed patients... - Pharmacological Treatment Patterns at Study Entry for the First 500 STEP-BD ParticipantsS Nassir Ghaemi
Department of Psychiatry at Emory University in Atlanta, Georgia 30322, USA
Psychiatr Serv 57:660-5. 2006..This study assessed patterns of psychopharmacological treatment for bipolar disorder... - A comparison of lithium and T(3) augmentation following two failed medication treatments for depression: a STAR*D reportAndrew A Nierenberg
Massachusetts General Hospital, 50 Staniford St, Boston, MA 02114, USA
Am J Psychiatry 163:1519-30; quiz 1665. 2006..This study compared the effectiveness of lithium versus triiodothyronine (T(3)) augmentation as a third-step treatment for patients with major depressive disorder... - The effects of psychotherapy, nefazodone, and their combination on subjective assessment of disturbed sleep in chronic depressionRachel Manber
Department of Psychiatry and Behavioral Sciences, Stanford University, CA 94305, USA
Sleep 26:130-6. 2003..The purpose of the study was to compare the effects of psychotherapy, nefazodone, and their combination on subjective measures of sleep in patients with chronic forms of major depression... - Tranylcypromine versus venlafaxine plus mirtazapine following three failed antidepressant medication trials for depression: a STAR*D reportPatrick J McGrath
Depression Evaluation Service, New York State Psychiatric Institute, 1051 Riverside Dr, New York, NY 10032, USA
Am J Psychiatry 163:1531-41; quiz 1666. 2006.... - A multicenter, placebo-controlled study of modafinil augmentation in partial responders to selective serotonin reuptake inhibitors with persistent fatigue and sleepinessMaurizio Fava
Depression Clinical and Research Program, Massachusetts General Hospital, Boston, MA 02114, USA
J Clin Psychiatry 66:85-93. 2005.... - Pharmacotherapy of mood disordersMichael E Thase
University of Pennsylvania School of Medicine and Veterans Administration Medical Center, Philadelphia, Pennsylvania 19104, USA
Annu Rev Clin Psychol 4:53-91. 2008.... - Anxiety disorder comorbidity in bipolar disorder patients: data from the first 500 participants in the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD)Naomi M Simon
Center for Anxiety and Traumatic Stress Related Disorders, Wang ACC 815, Massachusetts General Hospital, 15 Parkman St, Boston, MA 02114, USA
Am J Psychiatry 161:2222-9. 2004..The authors provide a detailed perspective on the correlates of comorbid anxiety in a large, well-characterized sample of bipolar disorder patients... - Therapeutic reactance as a predictor of outcome in the treatment of chronic depressionBruce A Arnow
Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, California 94305 5722, USA
J Consult Clin Psychol 71:1025-35. 2003..Results support the importance of Aptitude * Treatment interactions in psychotherapy outcome. The direction and significance of such interactions may vary with different forms of psychopathology... - Effectiveness of adjunctive antidepressant treatment for bipolar depressionGary S Sachs
Bipolar Clinic and Research Program, Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
N Engl J Med 356:1711-22. 2007..Our study was designed to determine whether adjunctive antidepressant therapy reduces symptoms of bipolar depression without increasing the risk of mania... - Psychosocial treatments for bipolar depression: a 1-year randomized trial from the Systematic Treatment Enhancement ProgramDavid J Miklowitz
Department of Psychology, University of Colorado, Boulder, CO 80309 0345, USA
Arch Gen Psychiatry 64:419-26. 2007..Psychosocial interventions have been shown to enhance pharmacotherapy outcomes in bipolar disorder... - Psychotherapy and medication in the treatment of adult and geriatric depression: which monotherapy or combined treatment?Steven D Hollon
Department of Psychology, Vanderbilt University, Nashville, TN 37203, USA
J Clin Psychiatry 66:455-68. 2005..The authors reviewed the literature with respect to the relative efficacy of medications and psychotherapy alone and in combination in the treatment of depression... - Incidence of sexual side effects in refractory depression during treatment with citalopram or paroxetineMikael Landen
Section of Psychiatry St Göran, Department of Clinical Neuroscience, Karolinska Institutet, SE 112 81, Stockholm, Sweden
J Clin Psychiatry 66:100-6. 2005.... - Intensive psychosocial intervention enhances functioning in patients with bipolar depression: results from a 9-month randomized controlled trialDavid J Miklowitz
Department of Psychology, University of Colorado, Boulder, CO 80309 0345, USA
Am J Psychiatry 164:1340-7. 2007..In a randomized trial, the authors examined the impact of intensive psychosocial treatment plus pharmacotherapy on the functional outcomes of patients with bipolar disorder over the 9 months following a depressive episode... - The Prevention of Recurrent Episodes of Depression with Venlafaxine for Two Years (PREVENT) study: outcomes from the acute and continuation phasesMartin B Keller
Brown University, Providence, Rhode Island 02906, USA
Biol Psychiatry 62:1371-9. 2007..We evaluated the comparative efficacy and safety of venlafaxine extended release (ER) and fluoxetine in the acute and continuation phases of treatment... - Comprehensive analysis of remission (COMPARE) with venlafaxine versus SSRIsCharles B Nemeroff
Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, Georgia 30322, USA
Biol Psychiatry 63:424-34. 2008..To compare venlafaxine and selective serotonin reuptake inhibitors (SSRIs; fluoxetine, sertraline, paroxetine, fluvoxamine, and citalopram) in the treatment of depression... - Treatment-resistant bipolar depression: a STEP-BD equipoise randomized effectiveness trial of antidepressant augmentation with lamotrigine, inositol, or risperidoneAndrew A Nierenberg
Massachusetts General Hospital Bipolar Clinic and Research Program, Suite 580, 50 Staniford Street, Boston, MA 02114, USA
Am J Psychiatry 163:210-6. 2006..This study represents the first randomized trial of competing options for treatment-resistant bipolar depression and assesses the effectiveness and safety of antidepressant augmentation with lamotrigine, inositol, and risperidone... - Predictors of recurrence in bipolar disorder: primary outcomes from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD)Roy H Perlis
Bipolar Clinical and Research Program, Massachusetts General Hospital, ACC 812, 15 Parkman Street, Boston, MA 02114, USA
Am J Psychiatry 163:217-24. 2006..The authors looked for the features associated with risk of recurrence... - The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled studyRonald N Marcus
Bristol Myers Squibb, Wallingford, CT 06492, USA
J Clin Psychopharmacol 28:156-65. 2008..1%] vs adjunctive aripiprazole [3.7%]). Aripiprazole is an effective and safe adjunctive therapy as demonstrated in this short-term study for patients who are nonresponsive to standard ADT... - Pharmacotherapy for bipolar disorder and comorbid conditions: baseline data from STEP-BDNaomi M Simon
Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA
J Clin Psychopharmacol 24:512-20. 2004..Our findings highlight the need for greater clinical guidance and treatment options for patients with bipolar disorder and comorbidity... - Adjunctive antidepressant use and symptomatic recovery among bipolar depressed patients with concomitant manic symptoms: findings from the STEP-BDJoseph F Goldberg
Affective Disorders Program, Silver Hill Hospital, New Canaan, Connecticut, USA
Am J Psychiatry 164:1348-55. 2007..However, few studies have examined the outcomes of patients with co-occurring manic and depressive symptoms who are treated with antidepressants plus mood stabilizing drugs... - Faster remission of chronic depression with combined psychotherapy and medication than with each therapy aloneRachel Manber
Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA 94305, USA
J Consult Clin Psychol 76:459-67. 2008..The authors conclude that combined antidepressant medications and psychotherapy result in faster full remission of chronic forms of major depressive disorder... - The effectiveness of St. John's Wort in major depressive disorder: a naturalistic phase 2 follow-up in which nonresponders were provided alternate medicationAlan J Gelenberg
University of Arizona Health Sciences Center, Tucson, AZ 85724, USA
J Clin Psychiatry 65:1114-9. 2004..A continuation study of an extract of St. John's wort (Hypericum perforatum) for depression was performed in follow-up to an acute study that found no significant difference between St. John's wort extract and placebo...